Meta-Analysis of the Effect of Chest Shielding on Preventing Patent Ductus Arteriosus in Premature Infants

Abstract

Objective This study aims to perform a meta-analysis of randomized studies to evaluate if chest shielding during phototherapy is associated with decreased incidence of patent ductus arteriosus (PDA) in premature infants.

Design/Methods We used published guidelines for the meta-analysis of clinical trials. The search strategy included electronic searches of CINAHL, CENTRAL Cochrane Library, MEDLINE, PubMed, and abstracts presented at the Pediatric Academic Societies. Inclusion criteria were randomized controlled trials (RCTs), quasi-RCTs or cluster RCTs published in English and involving chest shielding during phototherapy in premature infants with PDA as an outcome. Exclusion criteria involved case reports, case series, and multiple publications from the same author. Heterogeneity testing using Q statistics was performed to evaluate the variance between studies.

Results Two RCTs met study criteria. There was heterogeneity (I²: 55.4%) between the two trials. Meta-analysis of RCTs using the random effect model demonstrated that chest shielding during phototherapy was associated with decreased incidence of PDA (odds ratio: 0.47, 95% confidence interval: 0.23–0.96). There was no publication bias on Eggers test. Heterogeneity was seen in gestational age, gender, prophylactic use of postnatal indomethacin, duration of phototherapy, and assessment of PDA.

Conclusion Chest shielding during phototherapy may be associated with decreased incidence of PDA among premature infants.

Keywords

chest shielding - patent ductus arteriosus - hyperbilirubinemia - phototherapy

• References

• 1 Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117 (4) 1113-1121
• 2 Richards J, Johnson A, Fox G, Campbell M. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics 2009; 124 (2) e287-e293
• 3 Herrman K, Bose C, Lewis K, Laughon M. Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit. Arch Dis Child Fetal Neonatal Ed 2009; 94 (1) F48-F50
• 4 Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med 2000; 343 (10) 728-730
• 5 Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation 2006; 114 (17) 1873-1882
• 6 Skinner J. Diagnosis of patent ductus arteriosus. Semin Neonatol 2001; 6 (1) 49-61
• 7 Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39 (12) 1890-1900
• 8 Investigators of the Vermont-Oxford Trials Network Database Project. The Vermont-Oxford Trials Network: very low birth weight outcomes for 1990. Pediatrics 1993; 91 (3) 540-545
• 9 Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125 (5) 1020-1030
• 10 Amin SB. Clinical assessment of bilirubin-induced neurotoxicity in premature infants. Semin Perinatol 2004; 28 (5) 340-347
• 11 Xiong T, Qu Y, Cambier S, Mu D The side effects of phototherapy for neonatal jaundice: what do we know? What should we do? Eur J Pediatr 2011; 170 (10) 1247-1255
• 12 Sola A. Turn off the lights and the oxygen, when not needed: phototherapy and oxidative stress in the neonate. J Pediatr (Rio J) 2007; 83 (4) 293-296
• 13 Furchgott RF, Ehrreich SJ, Greenblatt E. The photoactivated relaxation of smooth muscle of rabbit aorta. J Gen Physiol 1961; 44: 499-519
• 14 Furchgott RF. Endothelium-dependent relaxation, endothelium-derived relaxing factor and photorelaxation of blood vessels. Semin Perinatol 1991; 15 (1) 11-15
• 15 Furchgott RF. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA 1996; 276 (14) 1186-1188
• 16 Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep 1999; 19 (4) 235-251
• 17 Clyman RI, Rudolph AM. Patent ductus arteriosus: a new light on an old problem. Pediatr Res 1978; 12 (2) 92-94
• 18 Barefield ES, Dwyer MD, Cassady G. Association of patent ductus arteriosus and phototherapy in infants weighing less than 1000 grams. J Perinatol 1993; 13 (5) 376-380
• 19 Liberati A, Altman DG, Tetzlaff J , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700
• 20 Kim HS, Kim EK, Lee HE , et al. Influence of phototherapy on incidence of patent ductus arteriosus in very low birth weight infants. Korean J Pediatr 1997; 40: 1410-1418
• 21 Rosenfeld W, Sadhev S, Brunot V, Jhaveri R, Zabaleta I, Evans HE. Phototherapy effect on the incidence of patent ductus arteriosus in premature infants: prevention with chest shielding. Pediatrics 1986; 78 (1) 10-14
• 22 Travadi J, Simmer K, Ramsay J, Doherty D, Hagan R. Patent ductus arteriosus in extremely preterm infants receiving phototherapy: does shielding the chest make a difference? A randomized, controlled trial. Acta Paediatr 2006; 95 (11) 1418-1423
• 23 Benders MJ, Van Bel F, Van de Bor M. Cardiac output and ductal reopening during phototherapy in preterm infants. Acta Paediatr 1999; 88 (9) 1014-1019
• 24 Noori S. Patent ductus arteriosus in the preterm infant: to treat or not to treat?. J Perinatol 2010; 30 (Suppl): S31-S37
• 25 Dice JE, Bhatia J. Patent ductus arteriosus: an overview. J Pediatr Pharmacol Ther 2007; 12 (3) 138-146
• 26 Schmidt B, Roberts RS, Fanaroff A , et al; TIPP Investigators. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 2006; 148 (6) 730-734
• 27 Salhab WA, Hynan LS, Perlman JM. Partial or complete antenatal steroids treatment and neonatal outcome in extremely low birth weight infants < or =1000 g: is there a dose-dependent effect?. J Perinatol 2003; 23 (8) 668-672
• 28 American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114 (1) 297-316